458 Brannan Street
162 articles with Invitae
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
Landmark data supporting universal genetic testing in cancer and the utility of germline and somatic testing to improve patient management published
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In
Taysha Gene Therapies Partners with Invitae to Enable Rapid Access to Genetic Testing and Earlier Diagnosis of Patients with CNS Disease for Rare and Large-Market Indications
Detect Lysosomal Storage Diseases program reduces barriers to genetic diagnosis through sponsored testing for lysosomal storage disorders, including GM2 gangliosidosis
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
-- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --
-- Brings expertise and leadership in scaling engineering and digital tools throughout her career as a tech entrepreneur --
Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer
-- 1 in 9 men will be diagnosed with prostate cancer in their lifetime -- -- Prostate cancer awareness month calls attention to need for research and testing -- [03-September-2020] SAN FRANCISCO , Sept. 3, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide stu
Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Monday, September 14, 2020 at 4:30 p.m. Eastern / 1:30 p.m. Pacific.
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
Introduced expanded services and support for transition to telehealth across customer types
Invitae Corporation, a leading medical genetics company, announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring
Invitae Corporation, a leading medical genetics company, announced that members of its management team will virtually present at the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020 at 9:20 a.m. Central / 7:20 a.m. Pacific.
Includes screening recommended in early pregnancy, as well as cancer risk assessment, guided by telehealth clinicians and completed at home
Invitae Reports More Than $64 Million in Revenue Driven by More Than 154,000 Samples Accessioned in the First Quarter of 2020
Invitae Corporation, a leading medical genetics company, announced financial and operating results for the first quarter ended March 31, 2020.
Clinical chatbot Gia offers new tools for OB/GYNs, oncologists, genetic counselors and other clinicians who order genetic testing
Invitae Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock and Closing of Underwritten Public Offering
Invitae Corporation announced the closing of its underwritten public offering of 20,444,444 shares of its common stock, including 2,666,666 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $9.00 per share.
Invitae Corporation announced the pricing of an underwritten public offering of 17,777,778 shares of its common stock at a price to the public of $9.00 per share.
Invitae Corporation announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.
Invitae to Acquire YouScript and Genelex to Make it Easier to Use Pharmacogenetic Information at the Point of Care
-- Unique combination of pharmacogenetic information with sophisticated, EMR-integrated software has been shown to reduce risk and improve outcomes --
Invitae Acquires Diploid, Maker of Artificial-Intelligence Engine to Enable Clinical Diagnosis Using Whole Genome Sequencing in Minutes
-- Adds to Invitae's competitive advantage by providing rapid answers to patients while further reducing the cost of genetic testing at scale --
Invitae preliminary 2019 financial results demonstrate strong momentum with nearly 60% growth in test volume and more than 45% growth in revenue year-over-year
Issues 2020 guidance of more than 725,000 samples accessioned and more than $330 million in revenue, reflecting a more than 50% annual growth in both volume and revenue